Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

The application has been submitted by the capital investment arm of insurance company Aviva and mixed-use developer Socius, ...

Tariffs would also increase costs for Florida seniors. They’d drive up costs for Medicare, which is one of the largest drug ...